Roumier, Mathilde
,
Paule, Romain
Vallée, Alexandre
Rohmer, Julien
Ballester, Marie
Brun, Anne-Laure
Cerf, Charles
Chabi, Marie-Laure
Chinet, Thierry
Colombier, Marie-Alice
Farfour, Eric
Fourn, Erwan
Géri, Guillaume
Khau, David
Marroun, Ibrahim
Ponsoye, Matthieu
Roux, Antoine
Salvator, Hélène
Schoindre, Yoland
Si Larbi, Anne-Gaëlle
Tchérakian, Colas
Vasse, Marc
Verrat, Anne
Zuber, Benjamin
Couderc, Louis-Jean
Kahn, Jean-Emmanuel
Groh, Matthieu
Ackermann, Félix
Article History
Received: 15 July 2020
Accepted: 3 November 2020
First Online: 14 November 2020
Compliance with Ethical Standards
:
: MR: investigator of NCT04315298 trial which investigates the efficacy and safety of sarilumab (licensed by Sanofi) in hospitalized patients with COVID-19; non-financial support from Novartis Pharma SAS, Bristol Myers Squibb, and Swedish Orphan Biovitrum (outside the submitted work). HS: non-financial support from Oxyvie; grants for Foch Foundation, Fonds de dotation pour la recherche en santé respiratoire, and Philips Foundation (outside the submitted work). GG: non-financial support from Bard (outside the submitted work). YS: non-financial support from Astra Zeneca, Novartis Pharma, Bristol Myers Squibb, Sanofi Aventis France, Shire France, Chugai Pharma France, and Pfizer SAS (outside the submitted work). JLC: personal fees and non-financial support from Novartis, Boehringer Ingelheim, and Astra Zeneca; grants and other from LVL Air Liquide, outside the submitted work. JEK: none. MG: consulting fees from GlaxoSmithKline and Astra Zeneca (outside the submitted work). FA: investigator of NCT04315298 trial which investigates the efficacy and safety of sarilumab (licensed by Sanofi) in hospitalized patients with COVID-19. All other authors declare that they have no conflict of interest.
Free to read: This content has been made available to all.